Roquefort Investments PLC (GB:ROQ) has released an update.
Roquefort Therapeutics has announced promising results for its STAT-6 siRNA in treating immunological diseases, marking a significant advancement in its pre-clinical development. This innovative siRNA therapy, which targets a key factor in Type 2 inflammatory diseases, has shown efficacy in in vitro models and is part of a broader portfolio aimed at oncology and immunology fields. The company is actively seeking out-licensing deals with Big Pharma to further validate and capitalize on its siRNA programs.
For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.
